Jacek Jassem

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo, Richard S. Finn, Shukui Qin et al. · The Lancet · 2018 · 5.4K citations · Full text

Medicine, Oncology, Pharmacology +12

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck

James A. Bonner, Paul M. Harari, J. Giralt et al. · New England Journal of Medicine · 2006 · 5.1K citations · Full text

Medicine, Oncology, Radiation Oncology +13

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

Aron Goldhirsch, Eric P. Winer, Alan S. Coates et al. · Annals of Oncology · 2013 · 3.7K citations · Full text

Medicine, Oncology, Breast Oncology +10

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.3K citations · Full text

Medicine, Oncology, Pharmacology +15

Panitumumab–FOLFOX4 Treatment and <i>RAS</i> Mutations in Colorectal Cancer

Jean‐Yves Douillard, Kelly S. Oliner, Salvatore Siena et al. · New England Journal of Medicine · 2013 · 2.2K citations · Full text

Medicine, Oncology, Pharmacology +15